Savara Receives Analyst Upgrade and Price Target Increase

Savara (SVRA) has received a rating upgrade from "Neutral" to "Buy" and a price target increase from $2.00 to $5.00 by HC Wainwright & Co. This suggests a positive outlook for the company and a favorable shift in market sentiment. The upgrade comes after a volatile period for Savara, with previous analyst ratings and price targets varying widely. Savara is a biopharmaceutical company focused on rare respiratory diseases, with its main program, molgramostim nebulizer solution, in Phase 3 development for autoimmune pulmonary alveolar proteinosis.

Savara Inc. (SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, has received a significant upgrade from "Neutral" to "Buy" by H.C. Wainwright & Co. The analyst firm also raised its price target for Savara from $2.00 to $5.00, reflecting a positive outlook on the company's prospects [1].

The upgrade comes after a tumultuous period for Savara, with previous analyst ratings and price targets varying widely. The catalyst for the upgrade is Savara's recent alignment with the U.S. Food and Drug Administration (FDA) regarding the Chemistry, Manufacturing, and Controls (CMC) data requirements for its Biologics License Application (BLA) for Molbreevi. The company plans to resubmit the BLA in December, with Fujifilm Diosynth Biotechnologies as the drug substance manufacturer, and will request priority review, potentially leading to a PDUFA date around August 2026 [2].

The decision to proceed with Fujifilm as the manufacturing partner was a key factor in H.C. Wainwright's more positive outlook on Savara's prospects. The extensive data generated from Process Performance Qualification campaigns at Fujifilm, combined with FDA alignment on analytical comparability analysis and CMC data requirements, reduces the risk of the filing being rejected [1].

Savara's financial position remains strong, with more cash than debt and a healthy current ratio of 11.08, despite the company currently burning through cash rapidly. The company reported ~$146M in cash and short-term investments as of June 30, 2025, and believes it is sufficiently capitalized into 1Q 2027 [3].

Other recent developments include Oppenheimer raising its price target for Savara to $6, Guggenheim adjusting its price target to $8 while maintaining a Buy rating, and H.C. Wainwright downgrading the stock to Neutral with a $2 price target due to concerns about the company's communication with investors and the FDA [1].

Savara continues to navigate regulatory challenges and investor sentiment, with its lead program, molgramostim nebulizer solution, in Phase 3 development for autoimmune pulmonary alveolar proteinosis. The company's goal is to provide these patients with the first and only pharmacologic treatment option.

References:
[1] https://in.investing.com/news/analyst-ratings/savara-stock-rating-upgraded-to-buy-by-hc-wainwright-on-bla-resubmission-plans-93CH-4967730
[2] https://seekingalpha.com/news/4486226-savara-stock-upgraded-hc-wainwright
[3] https://investors.savarapharma.com/news/news-details/2025/Savara-Reports-Second-Quarter-2025-Financial-Results-and-Provides-a-Business-Update/default.aspx